OncoMatch/Clinical Trials/NCT06431490
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Is NCT06431490 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies TQB2102 for for biliary tract cancer.
Treatment: TQB2102 for — To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 3+ or ihc 2+ with ish positive)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy
Failure of 1-2 prior lines of systemic therapy
Cannot have received: anti-HER2 therapy
Exception: only for the second stage, the first stage is not limited
Have previously received anti-HER2 therapy drugs (only for the second stage, the first stage is not limited)
Lab requirements
Blood counts
Kidney function
Liver function
The main organs function well
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06431490 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-HER2 therapy disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages